Bragar Eagel & Squire, P.C. Reminds Zoetis, Inc. Investors that a Class Action Lawsuit Has Been Filed Against Zoetis and Encourages Investors to Contact the Firm Before the July 27th Deadline

A class action lawsuit has been filed against Zoetis, Inc. for allegedly making materially false statements and failing to disclose material adverse facts about its business. The complaint alleges that Zoetis concealed weakening veterinarian adoption of its Librela product following FDA safety warnings, significant market share losses in Simparica Trio to competitors, and declining market share for dermatology products Apoquel and Cytopoint. Investors who purchased Zoetis securities between January 14, 2025 and May 6, 2026 have until July 27, 2026 to apply as lead plaintiff.